Literature DB >> 838874

Reduced oxidase activity in the caeruloplasmin of two families with Wilson's disease.

J L Gollan, J Stocks, T L Dormandy, S Sherlock.   

Abstract

Caeruloplasmin has been determined immunologically and by coper oxidase activity in 25 normal subjects, 20 patients with Wilson's disease, and 80 patients with chronic liver disease. Repeated estimation in four patients with Wilson's disease and two heterozygous mothers from two families revealed a consistent reduction in the copper oxidase activity of caeruloplasmin (12-32 units copper oxidase activity/mg caeruloplasmin) relative to the values obtained in normal subjects, patients with chronic liver disease, and other Wilson's disease patients (mean 65-79 units/mg). It is suggested that the functional abnormality in caeruloplasmin observed in these two families is an inherited variant, which does not appear to be due to the presence of a serum inhibitor of copper oxidase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 838874      PMCID: PMC476651          DOI: 10.1136/jcp.30.1.81

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Wilson's disease and the concentration of caeruloplasmin in serum.

Authors:  I H SCHEINBERG; I STERNLIEB
Journal:  Lancet       Date:  1963-06-29       Impact factor: 79.321

2.  The purification of human caeruloplasmin.

Authors:  G CURZON; L VALLET
Journal:  Biochem J       Date:  1960-02       Impact factor: 3.857

3.  Heterogeneity of human ceruloplasmin.

Authors:  A G MORELL; I H SCHEINBERG
Journal:  Science       Date:  1960-03-25       Impact factor: 47.728

4.  Genetic and biochemical aspects of Wilson's disease.

Authors:  A G BEARN
Journal:  Am J Med       Date:  1953-10       Impact factor: 4.965

5.  DETECTION OF THE HETEROZYGOUS CARRIER OF THE WILSON'S DISEASE GENE.

Authors:  I Sternlier; A G Morell; C D Bauer; B Combes; S De Bobes-Sternberg; I H Schein-Berg
Journal:  J Clin Invest       Date:  1961-04       Impact factor: 14.808

6.  A genetic study of Wilson's disease: evidence for heterogeneity.

Authors:  D W Cox; F C Fraser; A Sass-Kortsak
Journal:  Am J Hum Genet       Date:  1972-11       Impact factor: 11.025

7.  Prevention of Wilson's disease in asymptomatic patients.

Authors:  I Sternlieb; I H Scheinberg
Journal:  N Engl J Med       Date:  1968-02-15       Impact factor: 91.245

8.  A clinical and biochemical study of hepatolenticular degeneration (Wilson's disease).

Authors:  H BICKEL; F C NEALE; G HALL
Journal:  Q J Med       Date:  1957-10

9.  Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease).

Authors:  I H SCHEINBERG; D GITLIN
Journal:  Science       Date:  1952-10-31       Impact factor: 47.728

  9 in total
  2 in total

1.  Molecular studies of ceruloplasmin deficiency in Wilson's disease.

Authors:  M J Czaja; F R Weiner; S J Schwarzenberg; I Sternlieb; I H Scheinberg; D H Van Thiel; N F LaRusso; M A Giambrone; R Kirschner; M L Koschinsky
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study.

Authors:  Gudlaug Tórsdóttir; Grétar Gudmundsson; Jakob Kristinsson; Jón Snaedal; Torkell Jóhannesson
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.